Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Frater J. et al, (2021), Lancet HIV, 8, e474 - e485

Natural and vaccine-induced antibody and cellular responses against emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021)

Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV).

McNaughton AL. et al, (2019), Sci Rep, 9

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.

Smith D. et al, (2019), Hepatology, 69, 1861 - 1872

Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes

Mcnaughton A. et al, (2018), JOURNAL OF HEPATOLOGY, 68, S762 - S762

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.

von Delft A. et al, (2018), Vaccine, 36, 313 - 321

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F. et al, (2018), Front Immunol, 9

Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.

Bonsall D. et al, (2018), Infect Drug Resist, 11, 1119 - 1135

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.

van der Ree MH. et al, (2017), Antiviral Res, 146, 139 - 145

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.

Stelma F. et al, (2017), Hepatology, 66, 57 - 68

Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus.

Brown A. et al, (2016), Hepatology, 64, 1934 - 1950

Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.

Thomson E. et al, (2016), J Clin Microbiol, 54, 2470 - 2484

T Cell Functionality in Chronic Hepatitis C Patients Treated With the Anti-miR-122 RG-101

Stelma F. et al, (2016), HEPATOLOGY, 64, 731A - 731A

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Swadling L. et al, (2016), Vaccines (Basel), 4

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Kelly C. et al, (2016), Hepatology, 63, 1455 - 1470

Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.

Bonsall D. et al, (2016), Emerg Infect Dis, 22, 671 - 678

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.

von Delft A. et al, (2016), Gut, 65, 112 - 123

Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report.

Mora-Peris B. et al, (2015), AIDS, 29, 982 - 985

Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.

Kelly C. et al, (2015), Eur J Immunol, 45, 309 - 316

Global distribution and prevalence of hepatitis C virus genotypes

Messina JP. et al, (2015), Hepatology, 61, 77 - 87

Load More